Search results
Results from the WOW.Com Content Network
An artificial heart is a device that replaces the heart.Artificial hearts are typically used as a bridge to heart transplantation, but ongoing research aims to develop a device that could permanently replace the heart when a transplant—whether from a deceased human or, experimentally, from a genetically engineered pig—is unavailable or not viable.
A bioartificial heart is an engineered heart that contains the extracellular structure of a decellularized heart and cellular components from a different source. Such hearts are of particular interest for therapy as well as research into heart disease. The first bioartificial hearts were created in 2008 using cadaveric rat hearts.
An artificial heart valve is a one-way valve implanted into a person's heart to replace a heart valve that is not functioning properly (valvular heart disease).Artificial heart valves can be separated into three broad classes: mechanical heart valves, bioprosthetic tissue valves and engineered tissue valves.
AbioCor was a total artificial heart (TAH) developed by the Massachusetts-based company AbioMed. It was fully implantable within a patient, due to a combination of advances in miniaturization, biosensors, plastics and energy transfer. The AbioCor ran on a rechargeable source of power.
A pacemaker, also known as an artificial cardiac pacemaker, is an implanted medical device that generates electrical pulses delivered by electrodes to one or more of the chambers of the heart. Each pulse causes the targeted chamber(s) to contract and pump blood, [ 3 ] thus regulating the function of the electrical conduction system of the heart .
The Björk–Shiley valve is a mechanical artificial heart valve. The valve was co-invented by American engineer Donald Shiley and Swedish heart surgeon Viking Björk. Beginning in 1971, it has been used to replace aortic valves and mitral valves. It was the first successful tilting-disc valve.
Tissue engineered heart valves (TEHV) offer a new and advancing proposed treatment of creating a living heart valve for people who are in need of either a full or partial heart valve replacement. Currently, there are over a quarter of a million prosthetic heart valves implanted annually, [ 1 ] and the number of patients requiring replacement ...
Prosthetic heart valves, including the Hancock Aortic Tissue Valve, are not without drawbacks. Structural degradation is a risk, potentially necessitating reoperation. [ 13 ] [ 3 ] Studies have indicated the need for ongoing research and improvement in bioprosthetic valve technology to address such concerns [ 13 ]